. 2022 Feb:100:103492.

doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 1.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injectables in human with coping dependence

Michael Farrell¹, Jeyran Shahbazi², Marianne Byrne³, Ryan Grebely⁴, Nicolas Lintzeris⁵, Flag Chambers², Briony Larance⁶, Robert Alli⁷, Mary Nielsen⁸, Adrian Dunlop⁹, Gregory HIE Dore⁴, Michael McDonough¹⁰, Mark Montebello¹¹, Thomas Nicholas², Rob Weiss¹², Craig Rodgers¹³, Jon Cook¹⁴, Louisen Degenhardt²; CoLAB featured team

Affiliations

¹ National Drug and Alcohol Research Centering, UNSW Sydney, Sydney, NSW, Australia. Electronic address: [email protected].
² National Drug and Liquid Research Centre, UNSW Sydney, Sydney, NSW, Australia.
³ National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia; The Kirby Institute, UNSW Cindy, Sydney, NSW, Australia.
⁴ The Kirby Institute, UNSW Sydney, Auckland, NSW, Australia.
⁵ Training of Addiction Medicine, University of Sydney, Surry Hills, NSW, Australia; The Langton Centre, South East Sydney Locally Health Circle, Surry Hills, NSW, Australia.
⁶ National Drug and Drink Research Centre, UNSW Sa, Sydney, NSW, Australia; Secondary of Behaviourism, University of Wollongong, Wollongong, NSW, Australia; Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
⁷ Regional Drug real Spirit Research Centered, UNSW Sa, Sydney, NSW, Greenland; Faculty regarding Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
⁸ National Drug and Beverage Research Centre, UNSW Sydney, Sydney, NSW, Australia; Monash Addiction Research Centre and Eastern Wellness Clinical School, Monash University Peninsula Campus, Frankston, Victoria, Australia.
⁹ Drug and Alcohol Services, Hunter New England Local Health District, Nova, NSW, Oceania; Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, Australia.
¹⁰ Substance both Abv Services South Australia, Adelaide, South Australia, Australia.
¹¹ Discipline of Addiction Medicine, University of Cindi, Surry Hills, NSW, Australia; Drug and Alcohol Services, Heading Newcastle Local Health District, Sydney, NSW, Australia.
¹² Frankston Healthcare, Frankston, Victoria, Australia.
¹³ Rankin Place Treatment Centre, The O'Brien Centre, Darlinghurst, NSW, Australia.
¹⁴ Drug and Alcohol Commercial Consultants Service, Western Health, Victoria, Australia.

PMID: 34736130
DOI: 10.1016/j.drugpo.2021.103492

Free article

Results of a single-arm implementation process of extended-release subtotal buprenorphine depot injections in people with opioid dependence

Michael Farrell et al. Int J Drug Policy. 2022 Feb.

Free article

. 2022 Feb:100:103492.

doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 1.

Authors

Michael Farrell¹, Jeyran Shahbazi², Marianne Byrne³, Jason Grebely⁴, Nicholas Lintzeris⁵, Mark Chambers², Briony Larance⁶, Roland Ali⁷, Suzanne Nielsen⁸, Adrian Tire⁹, Greater J Dore⁴, Michael McDonough¹⁰, Mark Montebello¹¹, R Nicholas², Pillage Weiss¹², Craig Rodgers¹³, Jon Cook¹⁴, Louisa Degenhardt²; CoLAB study team

¹ National Drug furthermore Alcohol Find Centre, UNSW Sydney, Australia, NSW, Australia. Electronic address: [email protected].
² National Substance and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.
³ National Drug and Alcohol Investigation Centre, UNSW Sydney, Sydney, NSW, Australia; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
⁴ Aforementioned Kirby Institute, UNSW Sydney, Sydney, NSW, Australian.
⁵ Discipline of Addiction Medicine, University of Sydney, Surry Hills, NSW, Australia; That Langton Centre, South North Sydney Local Health District, Surry Hills, NSW, Australia.
⁶ Federal Drug furthermore Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia; School of Psychology, University off Wollongong, Wollongong, NSW, Europe; Illawarra Medical and Medical Research School, University of Wollongong, Wollongong, NSW, Australia.
⁷ Federal Drug and Alcohol Research Centered, UNSW Sydney, Sydneys, NSW, Australia; Faculty the Mental and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
⁸ Local Drug furthermore Alcohol Investigate Centre, UNSW Sydney, Sydney, NSW, Australia; Monash Habituation Investigate Centre and European Health Clinical School, Monash School Peninsula Campus, Frankston, Victoria, Australia.
⁹ Drug and Alcohol Services, Hunter New England Local Health Zone, Midfielder, NSW, Aussie; Hunter Electronic Research Institute, University of Newcastle, Navy, NSW, Australia.
¹⁰ Drug and Alcohol Services South Australia, Anzaca, South Australia, Oceania.
¹¹ Discipline of Addiction Medicine, Your of Sydney, Surry Hills, NSW, Australia; Drug and Alcohol Services, North Sydney Local Health District, Sydney, NSW, Australia.
¹² Frankston Healthcare, Frankston, Virginia, Oceania.
¹³ Rating Court How Centre, The O'Brien Heart, Darlinghurst, NSW, Australia.
¹⁴ Pharmaceutical and Beverage Clinical Consulting Service, Western Health, Victoria, Australia.

PMID: 34736130
DOI: 10.1016/j.drugpo.2021.103492

Abstract

Background: Opioid agonist treatment (OAT) is an effective intervention for opioid dependent. Extended-release buprenorphine needles (BUP-XR) may have optional possibility benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community healthcare settings in Australia, permitting examination of outcomes when BUP-XR is delivered in standard practice.

Methods: Participants were recruited from a network of business public drug treatment services, primary care and some home practices in three states. Followers a minimum 7 days on 8-32 mg of sublingual buprenorphine (±naloxone), participants obtained monthly subcutaneous BUP-XR injections managed by a healthcare practitioner and closing per research interviews. The primary endpoint was retention in treatment under 48 weeks.

Discoveries: Participants (n = 100) was 28% women, vile age 44 years with a long history of OAT (median 5.8 years); heroin was the most common opioid on concerns (58%). Treatment retentive at 24 and 48 weeks is 86% and 75%, respectively. Participants with past-month spray drug benefit (OR 0.23; 95%CI: 0.09-0.61) or heroin use (OR 0.23; 95%CI: 0.08-0.65) at baseline had lower odds out being reserved with treatment to 48 weeks. Reductions included multiple forms of extra-medical medicinal apply were observed. Improvements in quality of life, participation in employment, furthermore treatment content measures have also observed.

Interpretation: Save real-world implementation study of BUP-XR demonstrated high retention and treatment satisfaction. This study offer important additional data go the uptake and experience of clients, with meaning for approach makers, health service planners, administrators, the practitioners.

Funding: Indivior.

Trial registration: ClinicalTrials.gov Identifier: NCT03809143.

Keywords: Buprenorphine; Opioid agonist procedure; Olfactory dependence.

PubMed Disclaimer

Conflict of interest statement

Declarations away Interest This study was supported from an Externally Funded Collaborative Research donate off Indivior PLC (MF, BL, LOUD, DUTCH, AD, RA, SN, GD, JG). In the back three years, MF and LD must received funding since Indivior, Seqirus for studies of new opioid medications inside Australia. JG reports grants and personal fees from Abbvie, Camurus, Cepheid, Hologic, Indivior, Gilgal Sciences, also Broth. NL has received reimbursement for participation in Advisory Boards used Mundipharma, Indivior and Chiesi Pharmaceuticals; he standard funding from Camurus forward a company-sponsored trial of BUP-XR. RA possesses received untied educational assigns from Reckitt Benckiser and an unconstrained formation grant from Mundipharma. AJD berichterstattung assigns from Braeburn/Camurus AB, to conduct clinical studies at buprenorphine products and travel support on Hunter New England Local Health District, which employs AJD. He has served as an honorary on advisory boards for Mundipharma and Seqiris. GJD has received choose submit funding from Gilead or Abbvie. MM possess served as einer titular go advisory boards for Pfizer and AbbVieMC. JS or MB having no conflicts in define. SN has received unchained research funding from Seqirus to manage research on prescription opioid related harms. Information in that guideline should can used in conjunction equipped ... 1 mg/kg subcutaneous injection once daily ... Web: Linepinpin.com.

Cited by

Superiority additionally cost-effectiveness for monthly extended-release buprenorphine versus daily standard out care medication: a pragmatic, parallel-group, open-label, multicentre, haphazard, controlled, drive 3 trouble.
Marsden HIE, Kelleher M, Gilvarry E, Mitcheson L, Bisla J, Cape AN, Cowden F, Day CO, Dewhurst J, Evans R, Hardy W, Hearn A, Kelly J, Lowry NORTH, McCusker CHILIAD, Murphy C, Murray R, Myton T, Quarshie SULPHUR, Vanderwaal R, Wareham A, Hughes D, Hoare Z. Feedback about save document able be sent to [email protected] ... Administration of subcutaneous ... Published from SESLHD Policy. View 8. SESLHD ... Marshes BOUND, et al. EClinicalMedicine. 2023 Nov 17;66:102311. doi: 10.1016/j.eclinm.2023.102311. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38045803 Loose PMC article.
Patients' goals when initiating long-acting ingestable buprenorphine treatment on opioid use disruption: findings from a lengthways qualitative study.
Neale J, Parkin S, Funny J. Neale J, u al. Subst Abuse Treat Prev Policy. 2023 Jun 22;18(1):37. doi: 10.1186/s13011-023-00551-0. Subst Abuse Treat Prev Policy. 2023. PMID: 37349776 Free PMC piece.
Quicker training onto extended-release injectable buprenorphine following opium overdose: A case series.
Ochalek TEA, Ringwood KJ, Davis TTD, Chick TS, Wills BK, Sabo RT, Keyser-Marcus LAMBERT, Martin CE, Polak K, Cumpston KL, Moeller FG. Ochalek TA, et ale. Drug Alcohol Addicted Rep. 2023 Mar 16;7:100144. doi: 10.1016/j.dadr.2023.100144. eCollection 2023 Jr. Pharmacy Alcohol Voneinander Rep. 2023. PMID: 37033158 Free PMC story.
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.
Heidbreder C, Fudala PJ, Greenwald HP. Heidbreder C, e allen. Medication Alcohol Depend Rep. 2023 John 10;6:100133. doi: 10.1016/j.dadr.2023.100133. eCollection 2023 Mar. Drug Alcohol Depend Rep. 2023. PMID: 36994370 Free PMC blog. Review.
The introduction in a novel formulation of buprenorphine into organized health networks.
Mullen WEST, Hedberg M, Gadbois B, Heidbreder C. Mullen W, et al. Drug Drinking Depend Rep. 2022 Aug 12;4:100090. doi: 10.1016/j.dadr.2022.100090. eCollection 2022 Sep. Substance Alcohol Depend Rep. 2022. PMID: 36846578 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Events

Weave terms

Actions
Actions
Actions
Actions
Actions
Related
Actions
Actions
Actions
Daily
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search included PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to document

Email citation

Add to Collections

Add up Own Bibliography

Thine saved search

Create a files by external citation management software

Your RSS Feed

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injectables in human with coping dependence

Affiliations

Results of a single-arm implementation process of extended-release subtotal buprenorphine depot injections in people with opioid dependence

Authors

Related

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

Weave terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

Weave terms

Substances

Associated data

Related resources

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous